Shares Magazine
1,300.00p+0.00 (+0.00%)21 Nov 2024, 16:04
Jump to:
4Basebio PLC Fundamentals
| Company Name | 4Basebio PLC | Last Updated | 2024-11-21 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 12.811 m | Market Cap | £166.54 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.62 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | -2.2859 | Cash Equity Ratio | -0.5209 |
| Quick Ratio | 1.5346 | Current Ratio | 2.73 |
| Price To Book Value | 0 | ROCE | 0 |
4Basebio PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
4Basebio PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £4.20 m | £3.63 m | £2.76 m |
| Intangible Assets | £2.67 m | £2.12 m | £1.27 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £6.90 m | £5.79 m | £4.06 m |
| Stocks | £332,000.00 | £133,000.00 | £156,000.00 |
| Debtors | £107,000.00 | £54,000.00 | £46,000.00 |
| Cash & Equivalents | £3.07 m | £4.35 m | £9.59 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £11.92 m | £11.69 m | £14.70 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £2.28 m | £1.52 m | £1.52 m |
| Creditors after 1 year | £10.14 m | £3.05 m | £1.48 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £12.41 m | £4.57 m | £3.01 m |
| Net assets | -£492,000.00 | £7.12 m | £11.70 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £11.13 m | £11.13 m | £11.13 m |
| Share Premium | £706,000.00 | £706,000.00 | £706,000.00 |
| Profit / Loss | -£8.35 m | -£5.93 m | -£3.64 m |
| Other Equity | -£492,000.00 | £7.12 m | £11.70 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | -£492,000.00 | £7.12 m | £11.70 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | 0 | £0.29 | £0.10 |
| Debt-to-Equity | 0 | £0.41 | £0.11 |
| Assets / Equity | -2.2859 | -2.2859 | -2.2859 |
| Cash / Equity | -0.5209 | -0.5209 | -0.5209 |
| EPS | -£0.62 | -£0.42 | -£0.24 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£6.18 m | -£4.70 m | -£2.74 m |
| Cashflow before financing | £247,000.00 | -£3.46 m | -£3.21 m |
| Increase in Cash | -£1.24 m | -£5.40 m | -£4.72 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £506,000.00 | £268,000.00 | £338,000.00 |
| Cost of sales | £166,000.00 | £29,000.00 | £69,000.00 |
| Gross Profit | £340,000.00 | £239,000.00 | £269,000.00 |
| Operating Profit | -£8.05 m | -£5.84 m | -£3.53 m |
| Pre-Tax profit | -£8.35 m | -£5.93 m | -£3.64 m |
4Basebio PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | 4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use. |
| Latest Interim Date | 27 Sep 2024 |
| Latest Fiscal Year End Date | 5 Jun 2024 |
4Basebio PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2021-02-12 | Mr. Timothy Paul McCarthy | Non-Executive Director,Chairman |
| 2024-09-21 | Dr. Joseph M. Fernandez | Non-Executive Director |
| 2024-06-28 | Mr. Hansjorg Plaggemars | Non-Executive Director |
| 2024-11-19 | Dr. Heikki Lanckriet, PhD | Executive Director,Chief Executive Officer |
| 2024-09-21 | Mr. David John Roth | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-09-21 | Dr. Amy Jo Walker | Executive Director,Chief Operating Officer |
4Basebio PLC Contact Details
| Company Name | 4basebio PLC |
|---|---|
| Address | 25 Norman Way, Over, Cambridge, CB24 5QE |
| Telephone | +44 1223967943 |
| Website | https://www.4basebio.com |
4Basebio PLC Advisors
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
